Drug interactions between ifosfamide and Zyban
| Results for the following 2 drugs: |
|---|
| ifosfamide |
| Zyban (bupropion) |
Interactions between your selected drugs
bupropion ↔ ifosfamide
Applies to:Zyban (bupropion) and ifosfamide
MONITOR: Coadministration with inhibitors or substrates of CYP450 2B6 may increase the plasma concentrations of bupropion, which is primarily metabolized by the isoenzyme. The interaction has been demonstrated with both clopidogrel and ticlopidine, which are CYP450 2B6 inhibitors. In 12 healthy male volunteers, pretreatment with clopidogrel (75 mg orally once daily for 4 days) increased the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of bupropion (150 mg single oral dose) by 40% and 60%, respectively, compared to administration of bupropion alone. The AUC of the hydroxybupropion metabolite decreased by 52% and the AUC ratio of hydroxybupropion to bupropion decreased by 68% with clopidogrel, while oral clearance decreased by 26%. Similarly, pretreatment with ticlopidine (250 mg orally twice daily for 4 days) increased the Cmax and AUC of bupropion (150 mg single oral dose) by 38% and 85%, respectively, compared to administration of bupropion alone. The AUC of the hydroxybupropion metabolite decreased by 84% and the AUC ratio of hydroxybupropion to bupropion decreased by 90% with ticlopidine, while oral clearance decreased by 36%.
MANAGEMENT: Caution is advised if bupropion is prescribed with a substrate or inhibitor of CYP450 2B6. Pharmacologic response to bupropion should be monitored more closely whenever a CYP450 2B6 substrate or inhibitor is added to or withdrawn from therapy, and the bupropion dosage adjusted as necessary. Patients should be advised to contact their physician if they experience potential symptoms of bupropion toxicity such as agitation, anxiety, tremor, insomnia, and seizures, or neuropsychiatric symptoms such as delusions, hallucinations, psychosis, impaired concentration, paranoia, and confusion.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
